An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
about
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancerImmunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsImmune responses to human cancer stem-like cells/cancer-initiating cellsTargeting caspases in cancer therapeuticsPeptide Vaccine Therapy in Colorectal CancerCrystal Structure of Swine Major Histocompatibility Complex Class I SLA-1*0401 and Identification of 2009 Pandemic Swine-Origin Influenza A H1N1 Virus Cytotoxic T Lymphocyte Epitope PeptidesMelanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma.Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene.Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.Enhancement of antitumor immunity using a DNA-based replicon vaccine derived from Semliki Forest virus.The proto-oncogene survivin splice variant 2B is induced by PDGF and leads to cell proliferation in rheumatoid arthritis fibroblast-like synoviocytes.An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes.Expression level of wild-type survivin in gastric cancer is an independent predictor of survival.Heat shock enhances the expression of cytotoxic granule proteins and augments the activities of tumor-associated antigen-specific cytotoxic T lymphocytesExpression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer.Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.New therapeutic targets in the management of urothelial carcinoma of the bladderPotential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.Advanced antigen delivery of murine survivin: chimeric virus-like particles in cancer vaccine researchAltered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individualsAberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.Identification of a novel human memory T-cell population with the characteristics of stem-like chemo-resistance.Exosome-driven transfer of tumor-associated Pioneer Translation Products (TA-PTPs) for the MHC class I cross-presentation pathway.Implication of chemo-resistant memory T cells for immune surveillance in patients with sarcoma receiving chemotherapy.Tumor-associated antigens for specific immunotherapy of prostate cancerHeat shock protein 90 targets a chaperoned peptide to the static early endosome for efficient cross-presentation by human dendritic cells.Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer.Subcellular Localization of Survivin Determines Its Function in Cardiomyocytes.Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition.Major histocompatibility complex class I (FLA-E*01801) molecular structure in domestic cats demonstrates species-specific characteristics in presenting viral antigen peptides.Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine
P2860
Q24801232-8CF90F22-772F-4401-97DB-1ADB0842AB54Q26781538-F09605AF-D46D-4204-A199-DE0FFA805FBFQ26781794-8B160A62-B145-40BA-8F83-8BCAF1486AFFQ26821986-78F70DCC-A7EF-4B79-A6BF-95624039F1DEQ26830336-8B4D4027-3783-4C62-9889-4297B62BB1C8Q27673392-26FB454D-3941-439A-ABF2-602435CFBA33Q30894063-CDEF9417-7250-4E24-9FB3-2B757C81E8E9Q33634679-D71E9400-EAE7-4E21-A585-2C8653294FE4Q33793930-9FB1270C-513B-4FD6-9B4B-9941AAA99557Q34070374-E2C377AE-09C9-4955-B583-F8E553D9A3EDQ35051440-77CEDF89-EA5F-4D86-9263-3370183BB464Q35114611-E21FC897-3703-470C-A727-C297614CA1CDQ35635793-E6F6EBE6-E52A-4538-87BA-924F9B61EC15Q35769842-2B374F3F-9BDB-40BF-ACF4-AFB654A536DAQ36066035-9BD207AF-E4A8-4D44-9742-D27E60ACD751Q36309865-C9424320-3E87-49D2-86CE-ACB55A96CF8EQ36615708-FF99CD39-C913-40E2-BB7C-A1F76BAB5DEEQ36725286-420417DC-AB37-467B-B65E-0221E50BB83EQ36998205-77047535-B375-418F-93BD-610B867DC060Q37064709-EF3DF090-1B14-45CC-8817-D8139C8D460EQ37305943-A69D308F-E861-4F42-B2ED-44FB382C6389Q37393594-B7F401BB-B555-4317-80F8-B36EFBD611B1Q39526556-B2E5E250-FD0F-42D0-AE0A-DDE8C7EF3BAEQ39592383-491FDE5B-0ABF-400E-A408-B5F112CC08B8Q39764766-5FEFE1D3-B6DB-4D0B-BA5B-715C257A0E52Q40140002-8AFC62F8-2C17-4F6C-B4FE-8E881766CA7FQ40595494-F949F201-D8CC-43EA-B37B-AC4A3098ADF8Q41298097-AD3834CE-6F03-4C42-A472-0A4A59ABAAB9Q41595465-E81FD12D-66EF-4374-86B5-EB923BE20777Q41977894-E7CA17DF-25F9-4D43-8141-DFABA6ED7B87Q42086369-6A154D43-C611-4A04-9B35-930065C18616Q42212985-5EE12778-C784-4273-A59C-305FAD0DE383Q43166550-0367A68F-55D6-42E1-A6B9-265CEB08DBC6Q47110332-1050BE7C-F460-454E-BC5B-679A938E975BQ47182581-ED53ED54-9EA5-4055-816C-BA809F92B2D0Q47562618-D14DFD23-2398-41D7-996A-BCEB9C444CF2Q51758973-03019890-54EF-48ED-B847-D62D30DDEE48Q56524291-795A06BD-1001-48C7-B5EA-B2BBE96EB7EF
P2860
An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
An HLA-A24-restricted cytotoxi ...... -associated protein, survivin.
@en
type
label
An HLA-A24-restricted cytotoxi ...... -associated protein, survivin.
@en
prefLabel
An HLA-A24-restricted cytotoxi ...... -associated protein, survivin.
@en
P2093
P921
P1476
An HLA-A24-restricted cytotoxi ...... r-associated protein, survivin
@en
P2093
Akiko Maeda
Hideyuki Ikeda
Junichi Yoda
Kenjiro Kamiguchi
Kouichi Hirata
Noboru Yamanaka
Noriyuki Sato
Takashi Sato
Toshihiko Torigoe
Yoshihiko Hirohashi
P304
P407
P577
2002-06-01T00:00:00Z